<?xml version="1.0" encoding="ISO-8859-1"?>
<?xml-stylesheet type="text/xsl" href="/prwebFeeds.xsl"?>
<rss version="2.0">
  <channel>
    <title>PRWeb.com Press Release Feed - PRWeb UK Press Release Account Feed</title>
    <link>http://www.prweb.com</link>
    <description>PRWeb.com Press Release Feed - Press Releases</description>
    <language>en</language>
    <image>
      <title>PRWeb Distribution Newswire</title>
      <url>http://www.prweb.com/images_v4/prweb_logo_hv2.jpg</url>
      <link>http://www.prweb.com</link>
      <width>200</width>
      <height>46</height>
    </image>
    <managingEditor>xml@emediawire.com</managingEditor>
    <webMaster>xml@emediawire.com</webMaster>
    <ttl>30</ttl>

<item>
    <title>BD Announces CE Marking of BD ProbeTec&#8482; Qx Amplified Assays to Improve Detection of Chlamydia trachomatis and Neisseria gonorrhoeae</title>
    <link>http://www.prweb.com/releases/2009/06/prweb2560934.htm</link>
    <description>
        <![CDATA[  <P>This next-generation BD Viper System with XTR technology enables laboratories to process a higher volume of tests automatically from swabs or urine samples, with significantly less labour and more reliable test results. This improvement in process efficiency may lead to a higher number of accurate diagnoses and more appropriate patient care for the two most common sexually transmitted infections - Chlamydia and gonorrhea.  If left untreated, these infections in women can lead to pelvic inflammatory disease, infertility, ectopic pregnancy and chronic pelvic pain. (PRWeb Jun 23, 2009)</P>
        <P>Read the full story at <a href="http://www.prweb.com/releases/2009/06/prweb2560934.htm">http://www.prweb.com/releases/2009/06/prweb2560934.htm</a></P>]]>
    </description>
    <guid isPermaLink="true">http://www.prweb.com/releases/2009/06/prweb2560934.htm</guid>
</item>

<item>
    <title>BD and FIND Achieve Milestone in Global Battle Against MDR-TB</title>
    <link>http://www.prweb.com/releases/2009/06/prweb2562614.htm</link>
    <description>
        <![CDATA[  <P>BD (Becton, Dickinson and Company; NYSE: BDX), a leading global medical technology company, and FIND (Foundation for Innovative New Diagnostics), a Swiss foundation that develops, evaluates and accelerates the implementation of new diagnostic tools for poverty-related diseases, today announced a significant price reduction in the cost of liquid culture testing for TB (Tuberculosis). (PRWeb Jun 23, 2009)</P>
        <P>Read the full story at <a href="http://www.prweb.com/releases/2009/06/prweb2562614.htm">http://www.prweb.com/releases/2009/06/prweb2562614.htm</a></P>]]>
    </description>
    <guid isPermaLink="true">http://www.prweb.com/releases/2009/06/prweb2562614.htm</guid>
</item>

</channel>
</rss>